Study guide

6.5 Minor Ailment Prescribing and Nonprescription Therapy

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

6.5 Minor Ailment Prescribing and Nonprescription Therapy

Key Takeaways Explain This Topic AI

Pharmacist minor ailment assessment follows structured frameworks (SCHOLAR-MAC, QuEST) to differentiate self-limiting conditions from 'red flags' requiring urgent medical referral.

GERD and dyspepsia self-care utilizes antacids, H2RAs, and short-term PPIs (2-4 weeks); alarm features (dysphagia, odynophagia, unintentional weight loss, hematemesis, new onset > 50 yr) mandate physician referral.

Atopic dermatitis requires aggressive barrier repair with emollients and stepwise topical corticosteroids (FTU dosing); potent steroids are avoided on thin-skinned facial and intertriginous areas.

Allergic rhinitis is treated first-line with intranasal corticosteroids; oral second-generation antihistamines provide symptom relief, while topical decongestants must be limited to <= 3-5 days to avoid rhinitis medicamentosa.

Emergency contraception options include levonorgestrel 1.5 mg (within 72h; double dose if BMI > 25 kg/m2 or CYP3A4 inducers), ulipristal acetate 30 mg (within 120h; wait 5 days before resuming hormonal contraceptives), and the copper IUD (up to 7 days).

Last updated: August 2026

Minor Ailment Prescribing Landscape and Clinical Assessment

Across Canadian provinces, the scope of pharmacy practice has expanded to authorize pharmacists to assess and prescribe for designated minor ailments (self-limiting, uncomplicated conditions that do not require laboratory or diagnostic imaging confirmation). Pharmacists perform a differential assessment, identify "red flag" alarm symptoms requiring medical referral, prescribe Schedule I/II/III or unscheduled therapies, and document/communicate interventions to primary care providers.

Systematic Clinical Assessment Frameworks +-------------------------------------------------------------------------+

  • | SCHOLAR-MAC ASSESSMENT FRAMEWORK |
  • +-------------------------------------------------------------------------+
  • | S - Symptoms (What are the primary presenting complaints?) |
  • | C - Characteristics (Quality, intensity, bilateral vs unilateral) |
  • | H - History (Previous episodes, timing, duration) |
  • | O - Onset (When did symptoms begin; acute vs insidious) |
  • | L - Location (Specific anatomical site of lesion or pain) |
  • | A - Aggravating Factors (What makes the condition worse?) |
  • | R - Relieving Factors (What makes the condition better?) |
  • | --------------------------------------------------------------------- |
  • | M - Medications (Prescriptions, OTC, natural health products, herbs) |
  • | A - Allergies (Drug allergies, excipients, reactions) |
  • | C - Conditions (Underlying medical comorbidities, pregnancy/lactation) |
  • +-------------------------------------------------------------------------+
  • Gastrointestinal Minor Ailments
  • Dyspepsia and Gastroesophageal Reflux Disease (GERD)

Alarm Features / Red Flags (Immediate Physician Referral): Dysphagia (difficulty swallowing), odynophagia (painful swallowing), unexplained weight loss, persistent vomiting, hematemesis, melena, anemia, jaundice, palpable abdominal mass, or new-onset dyspepsia in individuals aged > 50 > 50 > 50 years .

Self-Care & Pharmacological Options:

Antacids: Magnesium hydroxide/aluminum hydroxide ( Maalox , Mylanta ), calcium carbonate ( Tums ), sodium bicarbonate. Provide immediate (within 5-15 minutes) but short-duration ( 1 − 2 hours 1-2\text{ hours} 1 − 2 hours ) neutralization of gastric acid. Magnesium causes diarrhea; aluminum and calcium cause constipation.

Histamine-2 Receptor Antagonists ( H 2 H_2 H 2 ​ RAs): Famotidine ( 10 − 20 mg 10-20\text{ mg} 10 − 20 mg PO once or twice daily). Onset 30-60 minutes, duration 8-12 hours. Subject to tachyphylaxis (tolerance) with continuous daily use.

Proton Pump Inhibitors (PPIs): Omeprazole , Pantoprazole , Esomeprazole , Rabeprazole , Lansoprazole ( 20 mg 20\text{ mg} 20 mg daily). Irreversibly inhibit active H + / K + H^+/K^+ H + / K + ATPase pumps. Take 30 to 60 minutes before the first meal of the day . Recommended minor ailment duration is 2 to 4 weeks .

Constipation

Laxative Class Active Agents Mechanism of Action Clinical Application & Safety Pearls

Bulk-Forming Psyllium ( Metamucil ), Methylcellulose Absorbs water into fecal mass, increasing volume and stimulating peristalsis First-line for chronic prevention. Onset 12-72 hours. Must take with ≥ 250 mL \ge 250\text{ mL} ≥ 250 mL fluid to avoid esophageal/intestinal obstruction

Osmotic Agents Polyethylene Glycol 3350 ( RestoraLAX ), Lactulose , Magnesium Hydroxide Draws water osmotically into intestinal lumen, softening stool PEG 3350 ( 17 g 17\text{ g} 17 g daily) is first-line for acute and chronic constipation. Onset 24-96 hours. Well tolerated, minimal cramping

Stimulants Sennosides ( Senokot ), Bisacodyl ( Dulcolax ) Stimulates mucosal nerve plexus to increase intestinal smooth muscle motility Onset 6-12 hours (oral) or 15-60 min (suppository). First-line for opioid-induced constipation (combined with osmotic). May cause abdominal cramping

Stool Softeners Docusate Sodium ( Colace ) Anionic surfactant; lowers surface tension allowing water/lipids to penetrate stool Ineffective as monotherapy for constipation; used primarily to prevent straining post-MI or perianal surgery

Constipation Red Flags: Severe localized abdominal pain, fever, vomiting, rectal bleeding / hematochezia, unexplained weight loss, pencil-thin stools, or acute onset in individuals > 50 > 50 > 50 years.

Diarrhea and Hemorrhoids

Acute Diarrhea: Cornerstone of therapy is Oral Rehydration Therapy (ORT) . Loperamide ( 4 mg 4\text{ mg} 4 mg initial dose, then 2 mg 2\text{ mg} 2 mg after each unformed stool, max 8 mg/day 8\text{ mg/day} 8 mg/day OTC / 16 mg/day 16\text{ mg/day} 16 mg/day Rx) is a peripheral μ \mu μ -opioid agonist that slows motility. Contraindication: Avoid in bacterial dysentery (high fever, bloody stools) or suspected C. difficile / STEC colitis. Bismuth Subsalicylate ( Pepto-Bismol ) provides antisecretory/antimicrobial actions; causes harmless black tongue and dark stools (avoid in children due to Reye's syndrome risk, and in salicylate allergy).

Hemorrhoids: First-line includes high fiber, increased fluids, and warm sitz baths. Pharmacological: Topical astringents/protectants ( Zinc oxide ), local anesthetics ( Pramoxine ), and short-term topical corticosteroids ( Hydrocortisone 0.5 − 1 % 0.5-1\% 0.5 − 1% limited to ≤ 7 days \le 7\text{ days} ≤ 7 days to prevent perianal skin atrophy). Red Flags: Massive rectal bleeding, dark tarry stools, or excruciating sudden perianal pain suggesting thrombosed external hemorrhoids.

  • Dermatological Minor Ailments
  • Atopic Dermatitis (Eczema)

Atopic dermatitis involves epidermal barrier dysfunction and immune dysregulation.

Barrier Maintenance: Daily bathing with lukewarm water, soap-free cleansers, and immediate application of bland, fragrance-free emollients (ointments/creams preferred over lotions) to trap moisture.

Topical Corticosteroids (TCS): Applied in short bursts (1-2 weeks) during acute flares.

Potency Ladder:

Low Potency (Class VII): Hydrocortisone acetate 0.5 − 1 % 0.5-1\% 0.5 − 1% . Safe for face, neck, axillae, groin, and pediatric infants.

Moderate Potency (Class IV-V): Betamethasone valerate 0.05 − 0.1 % 0.05-0.1\% 0.05 − 0.1% , Clobetasone butyrate 0.05 % 0.05\% 0.05% , Triamcinolone 0.1 % 0.1\% 0.1% . Used on trunk and extremities.

High Potency (Class II-III): Mometasone furoate 0.1 % 0.1\% 0.1% , Betamethasone dipropionate 0.05 % 0.05\% 0.05% . Used on thick, lichenified plaques.

Ultra-High Potency (Class I): Clobetasol propionate 0.05 % 0.05\% 0.05% . Limited to palms, soles, and thick scalp lesions; duration ≤ 2 − 3 weeks \le 2-3\text{ weeks} ≤ 2 − 3 weeks .

Fingertip Unit (FTU): Amount squeezed from a 5 mm 5\text{ mm} 5 mm nozzle from the distal skin crease to the fingertip of an adult index finger ( 0.5 g 0.5\text{ g} 0.5 g ), covering the area of two adult handprints.

Steroid-Sparing Alternatives: Topical calcineurin inhibitors ( Tacrolimus 0.03 − 0.1 % 0.03-0.1\% 0.03 − 0.1% , Pimecrolimus 1 % 1\% 1% ) and PDE4 inhibitor ( Crisaborole 2 % 2\% 2% ). Do not cause skin atrophy, making them ideal for delicate facial and eyelid eczema.

Acne Vulgaris

Acne pathophysiology involves follicular hyperkeratinization, sebum hyperproduction, Cutibacterium acnes proliferation, and inflammation.

Mild Comedonal / Inflammatory Acne: First-line is Topical Benzoyl Peroxide (BPO 2.5 − 5 % 2.5-5\% 2.5 − 5% ) (antimicrobial, comedolytic; does not induce bacterial resistance; bleaches fabrics) and/or Topical Retinoids ( Adapalene 0.1 − 0.3 % 0.1-0.3\% 0.1 − 0.3% , Trifarotene , Tretinoin ; normalize keratinization; apply at night; cause skin peeling/photosensitivity; contraindicated in pregnancy ).

Moderate Papulopustular Acne: Combination of BPO + Topical Clindamycin 1 % 1\% 1% (fixed-dose combination Biacna , Clindoxyl ; always co-prescribe BPO with topical antibiotics to prevent resistance ) PLUS Topical Retinoid. If refractory, add oral tetracyclines ( Doxycycline 100 mg 100\text{ mg} 100 mg daily for ≤ 3 months \le 3\text{ months} ≤ 3 months ). Severe nodulocystic acne warrants Oral Isotretinoin (teratogenic; mandatory dual contraception).

Fungal Skin and Nail Infections

Tinea Pedis (Athlete's Foot) / Tinea Cruris (Jock Itch) / Tinea Corporis (Ringworm): Treat with topical allylamines ( Terbinafine 1 % 1\% 1% cream applied daily for 1-2 weeks) or topical azoles ( Clotrimazole 1 % 1\% 1% , Miconazole 2 % 2\% 2% , Ketoconazole 2 % 2\% 2% BID for 2-4 weeks). Continue treatment for 1-2 weeks after clinical resolution.

Tinea Capitis: Requires oral systemic antifungal therapy ( Terbinafine or Griseofulvin ); topical antifungals are ineffective for fungal hair shaft invasion.

Onychomycosis (Fungal Nail): Mild-to-moderate without matrix involvement: Efinaconazole 10 % 10\% 10% ( Jublia ) solution or Ciclopirox 8 % 8\% 8% nail lacquer applied daily for 48 weeks. Severe or matrix-involved: Oral Terbinafine ( 250 mg 250\text{ mg} 250 mg daily for 6 weeks in fingernails, 12 weeks in toenails; monitor baseline liver enzymes).

Cold Sores (Herpes Simplex Labialis)

Self-limiting HSV-1 vesicular lesions on lips. Treatment is most effective when initiated during the prodromal stage (tingling, burning before vesicles appear).

Pharmacotherapy: Topical Docosanol 10 % 10\% 10% ( Abreva , viral entry inhibitor) applied 5 times daily; or prescription Oral Valacyclovir ( 2 g 2\text{ g} 2 g PO BID for 1 day, separated by 12 hours).

Impetigo

Superficial bacterial skin infection ( S. aureus , S. pyogenes ) with classic "honey-colored" crusted erosions.

Localized non-bullous: Topical Mupirocin 2 % 2\% 2% or Fusidic Acid 2 % 2\% 2% ointment/cream TID for 5-7 days. Extensive/bullous: Oral Cephalexin .

  • Respiratory and ENT Minor Ailments
  • Allergic Rhinitis

Characterized by sneezing, rhinorrhea, nasal congestion, and itchy/watery eyes triggered by allergens (pollen, dust mites, animal dander).

Intranasal Corticosteroids (INCS): Fluticasone furoate/propionate , Mometasone furoate , Budesonide , Ciclesonide . First-line, most effective monotherapy for all nasal symptoms (including congestion) and ocular symptoms. Direct spray away from nasal septum to avoid epistaxis and septal perforation. Regular daily use is required for optimal efficacy.

Oral Antihistamines (Second-Generation): Cetirizine , Loratadine , Fexofenadine , Desloratadine , Bilastine , Rupatadine . Preferred over first-generation agents (diphenhydramine, chlorpheniramine) due to selective peripheral H 1 H_1 H 1 ​ blockade without anticholinergic sedation, cognitive impairment, or urinary retention.

Decongestants:

Oral Pseudoephedrine: Alpha-1 adrenergic vasoconstrictor. Use with caution in hypertension, ischemic heart disease, glaucoma, and benign prostatic hyperplasia.

Topical Decongestants (Oxymetazoline, Xylometazoline): Provide rapid nasal airflow improvement. Must be restricted to a maximum of 3 to 5 consecutive days to prevent Rhinitis Medicamentosa (rebound severe nasal congestion and mucosal dependency).

Eye and Ear Minor Ailments

Allergic Conjunctivitis: Bilateral itchy, watery eyes. Treat with Topical Dual Antihistamine/Mast Cell Stabilizers ( Olopatadine 0.1 − 0.2 % 0.1-0.2\% 0.1 − 0.2% , Ketotifen 0.025 % 0.025\% 0.025% ).

Bacterial Conjunctivitis: Unilateral or bilateral purulent discharge ("glued shut" eyelids in morning). Self-limiting; treat with topical Polymyxin B/Gramicidin ( Polysporin ) drops or Erythromycin ointment. Contact lens wearers require topical fluoroquinolone coverage ( Ciprofloxacin 0.3 % 0.3\% 0.3% ) to prevent Pseudomonas aeruginosa keratitis. Red flags: Eye pain, visual acuity loss, photophobia, ciliary flush, or corneal ulceration ⟹ \implies ⟹ urgent ophthalmology referral.

Otitis Externa (Swimmer's Ear): External canal inflammation/pain upon manipulation of tragus/pinna. Treat with topical Ciprofloxacin/Dexamethasone ( Ciprodex ) or Polymyxin B/Neomycin/Hydrocortisone drops. Aminoglycoside-containing drops (neomycin, tobramycin, gentamicin) are contraindicated if tympanic membrane perforation cannot be excluded due to risk of irreversible ototoxicity.

Musculoskeletal Minor Ailments: Sprains and Strains

Acute Soft-Tissue Injury Management: Follow the PEACE & LOVE protocol (Protect, Elevate, Avoid anti-inflammatory modalities in immediate 24-48h if severe tissue repair needed, Compress, Educate; followed by Load, Optimism, Vascularization, Exercise).

Topical vs. Oral NSAIDs: Topical Diclofenac Gel ( 1.16 % 1.16\% 1.16% or 2.32 % 2.32\% 2.32% ) is first-line for acute localized strains/sprains and knee/hand osteoarthritis. It provides equivalent analgesia to oral NSAIDs while resulting in > 90 % > 90\% > 90% lower systemic plasma concentrations, significantly reducing risks of GI bleeding, acute kidney injury, and cardiovascular events.

Red Flags (Ottawa Ankle Rules - Referral for Radiography): Bone tenderness along distal 6 cm 6\text{ cm} 6 cm of posterior edge of fibula/lateral malleolus or tibia/medial malleolus, bone tenderness at base of 5th metatarsal or navicular, or inability to bear weight both immediately and for 4 steps in clinic.

  • Reproductive and Women's Health Minor Ailments
  • Vulvovaginal Candidiasis (VVC)

Clinical Presentation: Vulvar pruritus, burning, dyspareunia, and thick, white "cottage cheese-like" non-malodorous discharge.

Pharmacological Treatment:

Topical Azoles: Clotrimazole ( 1 − 2 % 1-2\% 1 − 2% cream or 100 − 200 mg 100-200\text{ mg} 100 − 200 mg vaginal ovules for 1-7 days) or Miconazole vaginal suppositories.

Oral Azole: Fluconazole ( 150 mg 150\text{ mg} 150 mg PO single dose).

Pregnancy Warning: Oral fluconazole is contraindicated in pregnancy (associated with spontaneous abortion and congenital anomalies). Pregnant patients must be treated only with a 7-day topical azole regimen (e.g., clotrimazole 1 % 1\% 1% vaginal cream for 7 consecutive days).

Red Flags: Recurrent VVC ( ≥ 4 \ge 4 ≥ 4 episodes/year), severe intractable symptoms, premenarchal girls, abnormal vaginal bleeding, or fever/pelvic pain.

Dysmenorrhea

Primary Dysmenorrhea: Painful menstrual cramping occurring with ovulatory cycles in the absence of pelvic pathology. First-line therapy is NSAIDs ( Naproxen 500 mg 500\text{ mg} 500 mg initially then 250 mg 250\text{ mg} 250 mg q6-8h, Ibuprofen 400 mg 400\text{ mg} 400 mg q6h, or Mefenamic acid 500 mg 500\text{ mg} 500 mg then 250 mg 250\text{ mg} 250 mg q6h), initiated at onset of menses or 1-2 days prior. Second-line: Combined hormonal contraceptives.

  • Emergency Contraception (EC) +-------------------------------------------------------------------------+
  • | EMERGENCY CONTRACEPTION COMPARISON |
  • +-------------------------------------------------------------------------+
  • | |
  • | 1. LEVONORGESTREL 1.5 mg (*Plan B*, Unscheduled / Schedule III): |
  • | - Mechanism: Delays/inhibits LH surge and ovulation |
  • | - Window: Within 72 hours (up to 120h, but efficacy drops) |
  • | - Weight/BMI Rule: Efficacy decreases at BMI >= 25 kg/m2 or weight |
  • | > 70-80 kg. Preferred response is ulipristal or a copper IUD, |
  • | NOT a doubled levonorgestrel dose (a randomized trial found |
  • | 3.0 mg did not improve ovulation delay in obesity) |
  • | - Enzyme inducers: a 3.0 mg dose IS advised with CYP3A4 inducers |
  • | (e.g., carbamazepine, rifampin, St. John's wort); a copper IUD |
  • | remains the more reliable option |
  • | |
  • | 2. ULIPRISTAL ACETATE 30 mg (*Ella*, Schedule I / Prescribed): |
  • | - Mechanism: Selective Progesterone Receptor Modulator (SPRM); |
  • | inhibits ovulation even AFTER the LH surge has started |
  • | - Window: Up to 120 hours (5 days) with consistent high efficacy |
  • | - Superior to levonorgestrel in individuals with BMI >= 25-30 kg/m2 |
  • | - Critical Rule: Must wait 5 DAYS after ulipristal before resuming |
  • | or starting regular progestin-containing hormonal contraception |
  • | |
  • | 3. COPPER INTRAUTERINE DEVICE (Cu-IUD): |
  • | - Mechanism: Spermicidal copper ions prevent fertilization/implants |
  • | - Window: Inserted within 7 days post-unprotected intercourse |
  • | - Gold standard: > 99% efficacy regardless of body weight/BMI |
  • +-------------------------------------------------------------------------+